Deposition of fibrillar amyloid ␤-protein (A␤) in the brain is a prominent pathological feature of Alzheimer disease and related disorders, including familial forms of cerebral amyloid angiopathy (CAA). Mutant forms of A␤, including Dutch-and Iowa-type A␤, which are responsible for familial CAA, deposit primarily as fibrillar amyloid along the cerebral vasculature and are either absent or present only as diffuse non-fibrillar plaques in the brain parenchyma. Despite the lack of parenchymal fibril formation in vivo, these CAA mutant A␤ peptides exhibit a markedly increased rate and extent of fibril formation in vitro compared with wild-type A␤. Based on these conflicting observations, we sought to determine whether brain parenchymal factors that selectively interact with and modulate CAA mutant A␤ fibril assembly exist. Using a combination of immunoaffinity chromatography and mass spectrometry, we identified myelin basic protein (MBP) as a prominent brain parenchymal factor that preferentially binds to CAA mutant A␤ compared with wild-type A␤. Surface plasmon resonance measurements confirmed that MBP bound more tightly to Dutch/Iowa CAA double mutant A␤ than to wild-type A␤. Using a combination of biochemical and ultrastructural techniques, we found that MBP inhibited the fibril assembly of CAA mutant A␤. Together, these findings suggest a possible role for MBP in regulating parenchymal fibrillar A␤ deposition in familial CAA.
Extracellular deposition of amyloid ␤-protein (A␤) 2 in the brain is a prominent feature of Alzheimer disease and other related disorders (1) . A␤ is a 39 -43-amino acid peptide that exhibits a high propensity to self-assemble into ␤-sheet-containing oligomeric forms and fibrils (2) . A␤ peptides are proteolytically produced from the amyloid ␤-protein precursor (A␤PP), a large type I integral membrane protein, through sequential proteolysis by ␤-and ␥-secretase activities (3) (4) (5) (6) . Cerebral deposition of A␤ in the parenchyma can occur as diffuse plaques, with little surrounding pathology, or as fibrillar plaques associated with dystrophic neurons, neurofibrillary tangles, and inflammation (1) . Fibrillar A␤ deposition also occurs within and along primarily small and medium arteries and arterioles of the cerebral cortex and leptomeninges and in the cerebral microvasculature, a condition known as cerebral amyloid angiopathy (CAA) (7) (8) (9) . This condition accounts for up to 20% of all spontaneous primary intracerebral hemorrhages and is a key pathological lesion in nearly all patients with Alzheimer disease and certain related disorders. Accumulation of fibrillar cerebral vascular A␤ has been shown to cause degeneration and cell death of smooth muscle cells and pericytes in affected larger cerebral vessels and cerebral microvessels, respectively (9 -11) . Recent findings have implicated cerebral microvascular A␤ deposition in promoting neuroinflammation and dementia in Alzheimer disease (12) (13) (14) (15) .
There exist several familial monogenic forms of CAA resulting from specific point mutations within the A␤ sequence of the A␤PP gene (16 -21) . The most recognized example of familial CAA is the Dutch-type E22Q substitution in A␤ (16, 17, 22) . A more recently identified form of familial CAA is the Iowa-type D23N substitution in A␤ (21) . Both forms cause early and severe cerebral vascular amyloid deposition and are accompanied by only diffuse parenchymal A␤ deposits with the absence of fibrillar plaques (21, 22) . Dutch-type CAA is characterized by vascular amyloid-associated neuroinflammation and recurrent, often fatal intracerebral hemorrhages at midlife (23) (24) (25) , with little or no indication of neurofibrillary tangles and neuronal pathology (25) (26) (27) . In contrast to the Dutch-type disease, Iowatype CAA appears to be more localized to the cerebral microvasculature, and although cerebral hemorrhage is not common, ischemic damage is observed (21) . Also, neurofibrillary tangles and robust neuroinflammation can be found associated with the capillary amyloid in Iowa-type CAA (28) . Both Dutch-and Iowa-type CAAs are accompanied by progressive cognitive impairment that appears to be driven by the extensive vascular amyloid deposition (27) (28) (29) .
Previous in vitro studies from our laboratory (30, 31, 33, 34 ) and others (32) have clearly shown that both the Dutch-and Iowa-type mutations increase the fibrillogenic and cerebrovascular cell pathogenic properties of A␤ compared with wild-type A␤. It is noteworthy that the Dutch-type (E22Q) and Iowa-type (D23N) mutations are adjacent within the A␤ peptide and that both result in loss of a negative charge at their respective sites.
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and Alzheimer's Association Grant IIRG-06-26805. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 To whom correspondence should be addressed: Dept. We found that including each of these mutations together in the same A␤ peptide (Dutch/Iowa CAA double mutant A␤40 peptide (A␤40DI)) further enhances the fibrillogenic and pathogenic properties in vitro (34) . Furthermore, in transgenic mice, A␤40DI retains the characteristic pattern of in vivo deposition of the Dutch and Iowa mutant peptides, including extensive fibrillar amyloid deposition along the cerebral vasculature accompanied by predominantly diffuse A␤ accumulation in the brain parenchyma (35) . However, the reason as to why the Dutch-and Iowa-type mutations lead to preferential accumulation of fibrillar amyloid exclusively in the cerebral vasculature and not in the brain parenchyma is unclear. A number of naturally occurring "A␤ chaperone"-binding molecules that have been reported to modulate fibrillar assembly of the peptide have been identified. For example, apoE has been described to either promote or inhibit A␤ fibril formation in vitro (36 -40) . Subsequent studies have suggested that the dual effects of apoE are dependent on the isoform (apoE3 versus apoE4) and/or the extent of lipidation (41) (42) (43) . Similarly, apoJ, otherwise known as clusterin, is another chaperone that was identified to facilitate A␤ fibril formation in vitro and in vivo (44 -46) . Other reported A␤ chaperones that may influence A␤ fibril assembly include ␣ 1 -antichymotrypsin (47, 48) , transthyretin (49, 50) , proteoglycans (51, 52) , and gangliosides (53, 54) . In these reports, the study of the interaction of chaperones was restricted to wild-type A␤ peptides. The involvement of these A␤ chaperones in promoting or inhibiting CAA mutant A␤ fibril formation remains largely unknown. With this in mind, one approach we have taken is to identify molecules that preferentially bind to CAA mutant forms of A␤ and that may modulate their fibrillar assembly.
In this study, we identified myelin basic protein (MBP) as an endogenous brain protein that preferentially binds to familial CAA mutant forms of A␤. This was demonstrated by a combination of affinity chromatography of normal human brain homogenate and mass spectrometry analysis and confirmed by surface plasmon resonance (SPR) kinetic binding experiments. Furthermore, we show that MBP effectively inhibits the fibrillar assembly of CAA mutant A␤ by biochemical methods as well as by transmission electron microscopy (TEM) and atomic force microscopy (AFM). Therefore, we postulate that MBP may be involved, at least in part, in regulating the compartment-specific fibrillar deposition of CAA mutant A␤ within the brain.
MATERIALS AND METHODS
Reagents and Chemicals-A␤ peptides were synthesized by solid-phase Fmoc (N-(9-fluorenyl)methoxycarbonyl) amino acid chemistry, purified by reverse-phase high performance liquid chromatography, and structurally characterized as described previously (55) . N-terminally biotinylated A␤ peptides were purchased from American Peptide Company Inc. (Sunnyvale, CA). A␤ peptides were initially prepared in hexafluoroisopropyl alcohol, dried, and resuspended in Me 2 SO as described previously (56) . Purified human MBP (purchased from Chemicon International Inc., Temecula, CA) was resuspended in acidic buffer, dialyzed into phosphate-buffered saline (PBS), and stored at Ϫ70°C at 1 mg/ml. Purified bovine ␣-lactalbumin and thioflavin T were purchased from Sigma. Mouse anti-A␤ monoclonal antibody (mAb) 6E10 was purchased from Senetek (Napa, CA). Anti-A␤ mAb 3D6 was generously provided by Lilly. Anti-A␤ mAb 66.1 was prepared as described (57) . Mouse anti-MBP mAbs 384 and 382 were purchased from Chemicon International Inc. Biotinylation of mAbs was carried out using EZ-Link sulfosuccinimidyl 6Ј-(biotinamido)-6-hexanamidohexanoate (Pierce) according to manufacturer's instructions.
Thioflavin T Fluorescence Assay-Lyophilized A␤ peptides were first resuspended with Me 2 SO to 2.5 mM, diluted to 12.5 M in PBS, and then incubated at 37°C with rocking either alone or with 1.56 M MBP or bovine ␣-lactalbumin. Control samples containing 0.5% Me 2 SO and 1.56 M MBP or lactalbumin in PBS were also included. At each time point, 100-l samples of each reaction were placed in a 96-well microplate in triplicate, and 5 l of 100 M thioflavin T was added. The plate was mixed and incubated at 22°C in the dark for 10 min. Fluorescence was measured at 490 nm with an excitation wavelength of 446 nm in a SpectraMax spectrofluorometer (Molecular Devices, Sunnyvale, CA) using SoftMax Pro control software.
Immunohistochemistry-Tg2576 and Tg-SwDI transgenic mice were killed at 24 months, and the brains were removed and bisected through the mid-sagittal plane. Cerebral hemispheres were immersion-fixed with 70% ethanol overnight and subjected to increasing sequential dehydration in ethanol, followed by xylene treatment and embedding in paraffin. Sagittal sections were cut at 10-m thickness using a microtome, placed in a flotation water bath at 45°C, and then mounted on ColorFrost Plus slides (Fisher). Paraffin was removed from the sections by washing with xylene, and the tissue sections were rehydrated in decreasing concentrations of ethanol. Antigen retrieval was performed by treatment with proteinase K (0.001 mg/ml) for 5 min at 22°C. Immunostaining was performed using anti-A␤ mAb 66.1 (1:300 dilution). Primary antibody was detected with horseradish peroxidase-conjugated anti-mouse IgG and visualized with a stable diaminobenzidine solution (Invitrogen). Detection of fibrillar amyloid was performed by incubating the sections with 1% thioflavin S in PBS in the dark for 5 min at 22°C, followed by washing three times (3 min each) with 50% ethanol. Images were captured using an Olympus BX60 optical microscope and an Olympus DP10 charge-coupled device camera.
Affinity Chromatography of Human Brain Homogenate-To prepare affinity resins, biotinylated wild-type A␤40 peptide (A␤40WT) and A␤40DI were each redissolved in 20 mM NaHCO 3 buffer (pH 8.5) and applied to ImmunoPure immobilized streptavidin beads (Pierce) following the manufacturer's instructions. Immobilized ligands were cross-linked with 2 mM bis(sulfosuccinimidyl) suberate (Pierce) for 30 min with rocking at room temperature in 20 mM NaHCO 3 (pH 8.5). Crosslinking reactions were stopped by the addition of 1 M Tris-HCl (pH 7.4) to a final concentration of 20 mM. Homogenates of normal human brain frontal cortex were prepared in Tris-buffered saline (50 mM Tris-HCl and 200 mM NaCl (pH 7.4)) containing Complete protease inhibitor cocktail (Roche). Homogenates were centrifuged at 12,000 ϫ g for 30 min, and supernatants were loaded onto Tris-buffered saline-equili-brated affinity columns (0.8 ϫ 4 cm) under gravity flow. After extensive washing, the columns were eluted with 0.2 M glycine and 0.15 M NaCl (pH 2.7) and collected into tubes containing 200 mM Tris-HCl, 50 M iodoacetate, 50 M 4-(2-aminoethyl) benzenesulfonyl fluoride, 50 M EDTA, and 50 g/ml leupeptin. Fractions were analyzed by SDS-PAGE on 10 -20% Tris/ glycine gradient gels. All runs were carried out at 4°C. Three separate affinity chromatography runs were carried out for each column ligand.
Mass Spectrometry Analysis-Protein bands separated by SDS-PAGE were excised from the polyacrylamide gels and digested overnight with sequencing-grade trypsin in situ at 37°C. Samples were run on a Voyager-DE STR MALDI-TOF mass spectrometer (Applied Biosystems) operating in the reflector mode. Samples were dissolved in a 50% solution of acetonitrile and 0.1% trifluoroacetic acid containing ␣-cyano-4-hydroxycinnamic acid (5 mg/ml) and dried on the sample plate. A nitrogen laser operating at 337 nm was employed to ionize the sample. The accelerating voltage was set to 20 kV employing a 275-ns delay before introduction of ions into the flight tube of the mass spectrometer. The mass scale (m/z 500 -5000) was calibrated with a mixture of peptides (400 fmol/l), and ϳ100 laser shots were used to produce each spectrum. Peak lists were submitted to the Mascot search engine with no taxonomy limitation and a peptide tolerance set to 100 ppm.
Immunoblot Analysis-Briefly, samples were heated at 90°C for 5 min in reducing SDS-PAGE loading buffer, loaded onto gels, and electrophoresed. Gels were transferred to Hybond ECL nitrocellulose membranes (Amersham Biosciences) at 50 V overnight at 4°C. Membranes were blocked in PBS containing 5% milk or bovine serum albumin (BSA; used with biotinylated primary antibodies) at room temperature for 1 h and washed 3 ϫ 10 min with PBS and 0.05% Tween 20. Membranes were incubated with primary antibodies for 1 h and washed as described above. Next, the membranes were incubated with either horseradish peroxidase-conjugated sheep anti-mouse IgG or horseradish peroxidase-conjugated streptavidin (both from Amersham Biosciences) for 1 h and washed. Detection was accomplished using ECL Western blotting substrate (Pierce), and images were captured either on film or using a VersaDoc 3000 imaging system (Bio-Rad) and quantitated with the manufacturer's Quantity One software.
Co-immunoprecipitation-A␤ peptides were resuspended in Me 2 SO to 2.5 mM and used at 10.8 M. MBP was used at 1.56 M. Proteins were combined in 250 l of incubation buffer (PBS, 0.05% Tween 20, and 1% BSA). Anti-MBP mAb 382 was added to each sample mixture and incubated for 1 h at 4°C with rocking. After incubation, 20 l of washed GammaBind protein G-Sepharose beads (Amersham Biosciences) was added to each mixture, followed by incubation for an additional 1 h at 4°C with rocking. Beads were separated by centrifugation at 8000 ϫ g for 2 min. Supernatants were removed, and beads were washed with 1 ml of incubation buffer. Separation and washing were repeated three times. A final wash was performed in PBS and 0.05% Tween 20 to remove excess BSA. Centrifuged beads were combined with 25 l of reducing SDS-PAGE loading buffer and heated as described above. 10 l of each sample/ loading buffer mixture was loaded onto 10 -20% Tricine gels (Invitrogen) and electrophoresed at 125 V for 35 min. Immunoblotting was carried out as described above using either biotinylated anti-MBP mAb 384 or biotinylated anti-A␤ mAb 3D6 as primary antibody. Experiments were performed in triplicate.
Dot Blot Analysis-A␤ peptides and the A␤PP-(744 -763) and A␤PP-(100 -119) peptides (Multiple Peptide Systems, San Diego, CA) were diluted to 2 g/ml in Tris-buffered saline from 10 mg/ml Me 2 SO stock solutions. Insulin (Sigma) was resuspended to 2 mg/ml in water at pH 2.0 and diluted to 2 g/ml in Tris-buffered saline. 1 g of each was immobilized onto Hybond ECL nitrocellulose membranes using a Bio-Dot microfiltration apparatus (Bio-Rad) according to the manufacturer's instructions. Each membrane was removed from the apparatus following immobilization and blocked overnight in 5% BSA and PBS at 4°C. The membrane was then incubated in 1 g/ml MBP in 5% BSA, PBS, and 0.05% Tween 20 for 2 h at room temperature. The membrane was washed 3 ϫ 10 min with 5% BSA, PBS, and 0.05% Tween 20 and incubated with mAb 384 (1:2000 dilution) for 1 h at room temperature. The membrane was next washed 3 ϫ 10 min with PBS and 0.05% Tween 20 and incubated with horseradish peroxidase-conjugated sheep antimouse IgG (1:2000 dilution) for 1 h at room temperature. Detection and quantitation were performed as described above.
Surface Plasmon Resonance-All runs were performed on a Biacore 2000 instrument using 10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, and 0.005% (v/v) Tween 20 as running buffer and diluent. Streptavidin was conjugated to the surface of three flow cells of a CM5 chip at 10 l/min using amine coupling chemistry to a final average response level of 1890.2 response units. N-terminally biotinylated A␤ peptides were resuspended in Me 2 SO to 2.5 mM and serially diluted to 13 nM immediately before application. Biotinylated A␤40WT and A␤40DI were bound to individual flow cells at 10 l/min to achieve an average relative response level of 157.1 response units, leaving flow cell 1 as reference. This chip preparation procedure was found to result in a surface that minimized mass transfer effects for kinetic interaction experiments. The resultant R max of these surfaces was ϳ700 response units with MBP as analyte. Purified MBP was passed over all four flow cells at 5, 10, 25, 50, and 100 nM at a flow rate of 30 l/min for kinetic measurements. Faster flow rates did not significantly improve the quality of data. Surfaces were regenerated with 0.2 M glycine (pH 2.0) and 150 mM NaCl between runs. The resulting sensorgrams were analyzed by BIAanalysis software. Triplicate concentration series were used for each surface.
Immunoblot Analysis of A␤40DI Fibril Assembly-A␤40DI peptides were first resuspended in Me 2 SO to 2.5 mM, diluted to 12.5 M in PBS, and then incubated at 37°C with rocking in the presence or absence of 1.56 M MBP or lactalbumin. At each time point, 20 l was removed and combined with 20 l of SDS-PAGE loading buffer. The samples were heated as described above and frozen at Ϫ70°C until assayed. 5 l of each sample was analyzed for A␤ by quantitative immunoblotting using mAb 6E10 (1:2000 dilution) as described above. Each experiment was performed in triplicate.
Transmission Electron Microscopy-A 20-l aliquot of the sample mixture was deposited onto a Formvar-coated copper mesh grid. The sample was allowed to stand for 60 s, and excess solution was wicked away. The samples were negatively stained with 2% (w/v) uranyl acetate. The excess stain was wicked away, and the sample was allowed to dry. The samples were viewed with an FEI Tecnai 12 BioTwin transmission electron microscope, and digital images were taken with an Advanced Microscopy Techniques camera.
Atomic Force Microscopy-AFM was carried out using a lifeScan controller (LifeAFM Inc., Port Jefferson, NY) interfaced with a MultiMode microscope (Digital Instruments, Santa Barbara, CA) fitted with an E scanner. With this instrument configuration, only a single contact of the AFM probe is made with the sample per pixel. Computer control of the cantilever position and angle during approach allows for detection of the sample height with minimum cantilever deflection, allowing for a minimum compressive force (30 -100 piconewtons/ nm) applied to the sample. A complete description of the instrument and application to imaging of soluble A␤ oligomers has been reported (58) . AFM samples were prepared by adsorbing 20 l of sample mixture to freshly cleaved ruby mica (S & J Trading, Inc., Glen Oaks, NY) for 45 min to 1 h. The samples were rehydrated with ultrapure Milli-Q water (Millipore Corp., Billerica, MA) and immediately imaged. Samples were imaged using SuperSharpSilicon probes (SSS-CONT, NANOSENSORS, Neuchatel, Switzerland) that were modified for magnetic retraction by attaching samarium cobalt particles. We estimated the effective diameter of the SuperSharpSilicon probes to be 4 Ϯ 1 nm at a height of 2 nm. Data analysis and graphics were performed using Interactive Display Language Version 5.0 (Research Systems, Inc., Boulder, CO). In the Z-scale bars, numbers in each color square indicate the Z-value at the middle of the range for that color.
RESULTS

A␤40DI Displays Rapid Fibrillar Assembly in Vitro, but Little
Brain Parenchymal Assembly in Vivo-Dutch-and Iowa-type CAA mutant peptides display rapid fibril assembly in vitro (30 -34) . Here, we found that A␤40DI, containing both the Dutchand Iowa-type mutations, also exhibited markedly enhanced in vitro fibril assembly. A␤40DI showed rapid assembly compared with A␤40WT using the thioflavin T fluorescence assay as a measure of fibril formation (Fig. 1A) . The presence of abundant A␤40DI fibrils (Fig. 1B) and the lack of A␤40WT fibrils (Fig.  1C) was confirmed by TEM analysis.
Although A␤40DI displays very rapid fibril formation in vitro, fibrillar amyloid is restricted to the cerebral vasculature and is surprisingly absent in the brain parenchyma in vivo. This point is demonstrated by histological analysis of brain tissue from different transgenic mouse lines. The commonly used Tg2576 mouse model produces neuronally derived wild-type A␤ peptides (59) . Immunostaining Tg2576 mouse brain sections revealed abundant parenchymal A␤ deposits throughout the cortex and mostly in the brain gray matter (Fig. 2A) . Thioflavin S staining of Tg2576 brain sections showed abundant fibrillar parenchymal plaque deposits (Fig. 2C) . On the other hand, the Tg-SwDI mouse model produces neuronally derived Dutch/Iowa CAA mutant A␤ peptides (35) . Immunostaining Tg-SwDI mouse brain sections similarly showed abundant parenchymal A␤ accumulation throughout the cortex and again mostly in the brain gray matter (Fig. 2B) . However, in contrast to Tg2576, thioflavin S staining of Tg-SwDI brain sections showed no fibrillar parenchymal plaque deposits (Fig.  2D) . Fibrillar amyloid was restricted only to the cerebral microvasculature as focal deposits, as described previously (35) . The stark contrast between the rapid fibrillar assembly of A␤40DI in vitro and the lack of parenchymal fibrillar amyloid in Tg-SwDI mice suggests that unknown brain parenchymal factors may selectively influence CAA mutant fibril assembly and deposition in vivo.
MBP Preferentially Binds to CAA Mutant A␤40DI-We initially sought to identify brain proteins that may differentially interact with CAA mutant A␤40DI compared with A␤40WT. To do this, we prepared affinity columns with A␤40WT and A␤40DI by binding and cross-linking each N-terminally biotinylated A␤ peptide to streptavidin beads. Homogenate was prepared from normal human brain tissue and passed through each A␤40 peptide affinity column. After extensive washing, the bound proteins were eluted and analyzed by SDS-PAGE. As shown in Fig. 3B , a major band at ϳ20 kDa was eluted from the A␤40DI column. This protein was not present in the A␤40WT column elution. An additional protein band of ϳ65 kDa was also preferentially eluted from the A␤40DI column and not the A␤40WT column (Fig. 3) .
Mass spectrometry analysis was performed on a tryptic digest of the ϳ20-kDa band, yielding multiple peptides (Fig. 4) . The predicted sequences of nine of these peptides are shown in Table 1 . These peptides were determined to be homologous to MBP and had sequence homology of Ͼ50% to the 18.5-kDa splice variant. To confirm that the ϳ20-kDa protein eluted from the A␤40DI affinity column was indeed MBP, we performed immunoblot analysis on the eluates obtained from each of the columns. The ϳ20-kDa protein that eluted from the A␤40DI column was strongly recognized by mAb to MBP, as shown in Fig. 5 (lane 2) . No MBP was detected by immunoblot analysis of the eluate from the A␤40WT affinity column (Fig. 5, lane 1) .
Mass spectrometry analysis of a tryptic digest of the ϳ65-kDa band identified eight peptides, six of which were found to have homology to ORP7 (oxysterol-binding protein-related protein 7). However, the sequence homology for these six peptides was only 8%, and the remaining two peptides could not be matched to any protein (data not shown). ORP7 has a reported mass of ϳ95 kDa, which is distinct from the ϳ65-kDa band. In this study, we focused on MBP interactions with A␤40 peptides because this was the major species identified in the brain homogenate eluates.
Interaction of A␤ Peptides and MBP-To further investigate the interaction of MBP with Dutch/Iowa-type CAA mutant and wild-type A␤40 peptides, we performed co-immunoprecipitation experiments. Samples of MBP, MBP and A␤40WT, and MBP and A␤40DI were incubated with anti-MBP mAb 382 and precipitated with protein G-coated beads (Fig. 6A) . Duplicate immunoblot analysis was performed on each sample with either biotinylated anti-MBP mAb 384 or biotinylated anti-A␤ mAb 3D6. As shown in Fig. 6A , both A␤40WT and A␤40DI were precipitated with MBP in the assay. Neither A␤ peptide was pulled down in the absence of MBP. In addition, we also performed a quantitative dot blot analysis for MBP binding to A␤ and other peptides. Similar to the coimmunoprecipitation experiments, MBP exhibited binding to immobilized Dutch/Iowa mutant and wildtype A␤ peptides (Fig. 6, C and D) . In contrast, no MBP binding to other A␤PP peptides or insulin was observed.
The binding of A␤40WT and MBP in these experiments appears to contrast with the results presented in Figs. 3 and 5 , which sug- gested that A␤40WT does not bind MBP. However, the sample from which MBP was purified on the affinity columns was a total brain homogenate and most likely contained many competing factors that could have interfered with the binding between A␤40WT and MBP. On the other hand, the co-immunoprecipitation and dot blot analyses were performed using purified proteins free of any potential competing factors.
To more quantitatively analyze the interactions between MBP and A␤ peptides, we next performed SPR measurements. A␤40 peptide ligand surfaces and other assay parameters were designed to minimize the effects of mass transfer. By passing increasing concentrations of MBP over these surfaces and analyzing the resultant sensorgrams using BIAanalysis software, the kinetics of the interactions were determined. MBP bound more strongly to the Dutch/Iowa-type CAA double mutant A␤40DI, with K D ϭ 1.69 ϫ 10 Ϫ8 M. The strength of binding between MBP and A␤40WT was ϳ10-fold less, with K D ϭ 1.15 ϫ 10 Ϫ7 M.
MBP Inhibits CAA Mutant A␤40DI Fibril Formation in
Vitro-The results obtained above indicate that MBP preferentially binds to the more fibrillogenic A␤40DI compared with the much less fibrillogenic A␤40WT. We next determined whether this interaction could inhibit the fibrillar assembly of CAA mutant A␤40DI.
Using the thioflavin T fluorescence assay, we found that A␤40DI fibrillar assembly was dramatically prevented upon incubation in the presence of an 8-fold lower molar concentration of purified MBP (Fig. 7) . No change in A␤40DI thioflavin T fluorescence was seen in the presence of a similarly sized negative control protein (bovine lactalbumin) under these conditions. The inhibition of fibril assembly of the highly fibrillogenic A␤40DI by MBP was further examined by immunoblot analysis (Fig. 8) . A␤40DI (12.5 M) consisted of monomer and a range of intermediate oligomeric forms at the inception of the experiment and early in the incubation period, reflecting the strong propensity of this mutant form of A␤ to assemble (Fig. 8, A and  D) . Upon further incubation, assembly of very high molecular mass material was noted by 3 h, which continued to increase for up to 12 h. This increase in high molecular mass assembled peptide was accompanied by a strong concomitant loss of monomer and reduction in intermediate oligomers. The addition of 1.56 M MBP essentially prevented the progressive assembly of A␤40DI to high molecular mass assembled material (Fig. 8, C  and F) , leaving only monomer and intermediate oligomeric forms after 12 h. In the presence of the non-interacting control protein bovine lactalbumin (1.56 M), there was a minimum effect on the rate of fibril formation. These results suggest that, at substoichiometric concentrations, MBP effectively inhibits A␤40DI fibrillar assembly.
Inhibition of fibril assembly was confirmed by TEM and single-touch AFM analyses (Fig. 9) . At 6 h of incubation in the absence of MBP, A␤40DI formed dense networks of fibrils as observed by TEM (Fig. 9A) . In the presence of substoichiometric amounts of MBP, no evidence of fibril formation was found, and only amorphous aggregate staining was observed (Fig. 9B) . At an earlier time point of 3 h, high resolution single-touch AFM showed that A␤40DI formed long, well ordered fibrils with heights of ϳ4 nm and variable lengths (Fig. 9D) . In the presence of MBP at 3 h, A␤40DI peptides formed shorter, less-ordered oligomers and protofibrils with heights of ϳ2 nm and lengths of Ͻ200 nm (Fig.  9E) . TEM and AFM images of MBP alone showed that MBP did not aggregate significantly in these assays (Fig. 9, C and F,  respectively) .
DISCUSSION
Dutch-and Iowa-type familial CAA mutant A␤ peptides are known to be highly fibrillogenic in vitro. Moreover, A␤ containing both Dutch-and Iowa-type mutations together is markedly more fibrillogenic than that containing either single mutation alone (30, 34) . Yet despite these enhanced fibrillogenic properties in vitro, these CAA mutant forms of A␤ display little, if any, fibrillar deposition in the brain parenchyma in humans with these mutations or in transgenic mice expressing CAA mutant forms of these peptides in the central nervous system (21, 22, 35) . The reasons for this disparity remain unclear. We hypothesized that the brain parenchyma may contain factors that selectively bind to familial CAA mutant forms of A␤ and interfere with their fibrillar assembly and deposition within this specific compartment.
In this study, we have identified MBP as a prominent brain parenchymal factor that preferentially binds to CAA mutant A␤ containing both the Dutch and Iowa mutations and potently inhibits its assembly into fibrils. Similar to the affinity chromatography profiles (Fig. 3) , SPR kinetic binding experiments showed that MBP had stronger affinity for A␤40DI. It is somewhat surprising that an interaction between MBP and A␤40WT was observed in co-immunoprecipitation and dot blot experiments. However, SPR binding measurements showed that the interaction of MBP with A␤40WT was ϳ10-fold weaker than that with A␤40DI. Although this binding interaction was detected, we did not observe MBP in the eluate from the A␤40WT affinity column. It is possible that MBP was eluted from the A␤40WT column during the extensive washing steps prior to the elution of the column because of its weaker interaction. Alternatively, perhaps other factors in the total brain homogenate that influenced the interaction between MBP and A␤40WT were not present in the SPR or co-immunoprecipitation experiments using purified MBP.
Subsequently, we found that the interaction of MBP with the familial CAA mutant A␤40DI resulted in the inhibition of fibril formation as detected in thioflavin T fluorescence assays (Fig.  7) . Further analysis of the interaction between MBP and A␤40DI using quantitative immunoblotting, TEM, and AFM also demonstrated effective inhibition of high molecular mass assembly, yet intermediate oligomeric structures appeared unaffected (Figs. 8 and 9 ). The height of the fibrils and oligomers in the absence of MBP was measured to be ϳ4 nm (Fig.  9D) , whereas the height of the oligomers in the presence of MBP was reduced to slightly Ͼ2 nm (Fig. 9E) . Although the precise nature of the interaction between A␤40DI and MBP remains unclear, we speculate that MBP may inhibit fibril formation by capping oligomers and preventing the stacking of protofibrils.
These findings are consistent with the lack of thioflavin-positive parenchymal deposits in the brains of Dutch-or Iowa-type familial CAA patients or in transgenic mice expressing cerebral Dutch/Iowa CAA double mutant A␤ peptides (21, 35, 60) . Although fibrillar parenchymal A␤ deposits are absent in these brains, they do exhibit non-fibrillar diffuse accumulation in the parenchyma. Perhaps these diffuse parenchymal deposits are composed of intermediate oligomeric forms of A␤ similar to those we observed by AFM.
The gene encoding MBP belongs to a large family of developmentally regulated genes called the Golli complex (genes of the oligodendrocyte lineage) (61) (62) (63) . Members of this family are involved in the formation and maintenance of myelin sheaths. However, Golli proteins are also found in fetal spinal chord, thymus, spleen, and cells derived from the immune system (63), as well as in neurons (64, 65) . The Golli locus contains two distinct start sites under independent regulation and consists of 11 exons that can be alternatively spliced to form the various Golli-MBP proteins. Included are seven exons that encode the MBP proteins (62 It has been suggested that all of the Golli-MBP proteins exhibit little intrinsic structure, so they are unfolded in their native state (68, 69) . At least eight charge isomers have been shown to exist for the 18.5-kDa isoform. These result from deamidation, phosphorylation, C-terminal arginine loss, and the deimination of arginyl residues (70) . In many cases, these post-translational modifications are thought to regulate myelin assembly, MBP-ligand interactions, and signaling functions (71) . MBP interacts with many different ligands, including lipids (69, 72) , calmodulin (73) , divalent cations (74), GTP (75) , and cytoskeletal proteins such as tubulin (76) and actin (77) . The binding of MBP to tubulin and actin is believed to stabilize their polymerization, which is essential to the formation of myelin sheaths (78) .
Although Dutch-and Iowa-type A␤ peptides do not form amyloid in the parenchyma, they strongly assemble and deposit as fibrils in the cerebral vasculature (21) (22) (23) 26) . This suggests that specific factors in the parenchymal or cerebral vascular compartments of the central nervous system might differentially inhibit or enhance CAA mutant A␤ fibril formation. For example, we showed recently that specific gangliosides, which are found abundantly in cultured cerebrovascular cells and in isolated cerebral vessels, but not in the parenchyma, selectively promotes fibrillar assembly of these CAA mutant forms of A␤ (79) . On the other hand, MBP may represent a parenchymaderived factor that inhibits CAA mutant A␤ from assembling into parenchymal fibrillar deposits, thus allowing it to travel to the cerebral vasculature, where it rapidly assembles and accumulates as fibrillar amyloid.
There are several possibilities as to how MBP may interact with A␤ in vivo. For example, A␤ is produced largely by neurons in the brain and is released from axonal terminals (80, 81) . Myelin sheaths, which contain a high abundance of MBP derived from oligodendrocytes, insulate neuronal axons, and MBP is thereby within proximity to A␤. It is noteworthy that several Golli-MBP proteins are themselves expressed in neurons (64, 65) . It is significant that white matter in the brain, which is rich in MBP, is largely devoid of fibrillar amyloid deposition. This is supported by the near absence of A␤ deposits in white matter of transgenic mouse brain (Fig. 2) . Also, demyelination and white matter damage are pathological processes by which MBP could be further exposed to interaction with A␤. Finally, although MBP is present largely in the brain as a cellular protein, soluble forms of MBP are readily detected in the cerebrospinal fluid of normal individuals and are elevated in several neurological disorders (82, 83) . Thus, soluble forms of MBP are in position to interact with released A␤ peptides in the brain.
In conclusion, we have demonstrated that MBP preferentially interacts with CAA mutant forms of A␤ in vitro. Such an interaction may influence A␤ fibrillogenesis and deposition in the central nervous system. The ultimate test of the physiological relevance of this interaction will involve ongoing future studies in which CAA mutant A␤-depositing transgenic mice are placed on backgrounds of increased or decreased MBP expression to determine whether MBP influences the amount, form, or regional accumulation of A␤. Further investigation of this interaction may yield a better understanding of factors that govern regional amyloid deposition in the brain. Nevertheless, our findings suggest that MBP could serve as a novel platform for developing approaches to regulate pathological accumulation of CAA mutant (and perhaps wild-type) A␤ in disease.
